How much cash does Vor Biopharma generate?

Vor Biopharma (VOR) generated -$149.9M in operating cash flow over the trailing twelve months.

What is Vor Biopharma's free cash flow?

After $758.0K of capital expenditures, Vor Biopharma's free cash flow was -$150.7M over the trailing twelve months, down 49.7% year over year.

Where does Vor Biopharma's cash flow data come from?

Every line is extracted from Vor Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Vor Biopharma VOR Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	——	-$116.91M+0.8%	-$117.86M-28.0%	-$92.09M-33.7%
Depreciation and amortization	$2.95M-18.2%	$3.61M+2.2%	$3.53M+38.0%	$2.56M+81.9%
Stock-based compensation	$18.91M+92.1%	$9.85M-26.3%	$13.36M+24.9%	$10.7M+148%
Gain (loss) on sale of assets	——	——	——	——
Change in accounts payable	$10.93M—	——	$2.85M+156%	$1.11M+175%
Change in other assets	——	——	-$3.27M—	——
Change in operating lease liabilities	-$2.41M+37.2%	-$3.83M-6.9%	-$3.58M+65.7%	-$10.45M-309%
Net cash from operating activities	-$142.71M-43.2%	-$99.66M+0.6%	-$100.29M-17.8%	-$85.14M-23.1%
Capital expenditures	$941K+311%	$229K-78.6%	$1.07M-87.4%	$8.46M+117%
Net cash from investing activities	-$48.8M—	——	$71.01M+175%	-$94.09M-2.7%
Taxes paid for net share settlement	$254K-23.7%	$333K-71.9%	$1.19M—	——
Net cash from financing activities	$503.81M+843%	$53.42M+1,718%	$2.94M-97.5%	$117.14M-49.8%
Net increase (decrease) in cash	——	——	——	-$62.1M—
Depreciation	$2.95M-18.2%	$3.61M+2.2%	$3.53M+38.0%	$2.56M+81.9%
Operating lease liabilities	-$2.41M+37.2%	-$3.83M-6.9%	-$3.58M+65.7%	-$10.45M-309%
Increase (Decrease) in Other Operating Assets	$0+100%	-$2.43M-229%	$1.89M+162%	$721K+7.9%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	-$3.27M—	——
Payment Of Issuance Costs Related To Underwritten Public Offering And Private Placements	$1.33M-43.0%	$2.33M+224%	$717K—	——
Payments Of Stock Issuance Costs	——	——	——	——
Proceeds From Issuance Of Common Stock From Underwritten Public Offering Net Of Underwriting Discount And Commissions	$108.1M—	$0—	——	——
Common stock issuance for private placement	——	$55.55M—	——	——
Accrued payables for capital expenditures	——	——	——	——
Fair Value Adjustment Of Warrants	——	$0—	——	——
Increase Decrease In Operating Lease Liability	-$2.41M+37.2%	-$3.83M-6.9%	-$3.58M+65.7%	-$10.45M-309%
Issuance Costs Related To Private Placement Included In Accounts Payable And Accrued Expenses	——	——	——	——
Issuance Of Pre Funded Warrants In Connection With Acquisition Of In Process Research And Development	$177.38M—	$0—	——	——
Operating Lease Expense	$5.65M+12.0%	$5.04M+6.6%	$4.73M+29.9%	$3.64M+20.6%
Free cash flow	-$143.65M-43.8%	-$99.89M+1.5%	-$101.36M-8.3%	-$93.61M-28.2%
Free cash flow	-$143.65M-43.8%	-$99.89M+1.5%	-$101.36M-8.3%	-$93.61M-28.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Vor Biopharma generate?: Vor Biopharma (VOR) generated -$149.9M in operating cash flow over the trailing twelve months.
What is Vor Biopharma's free cash flow?: After $758.0K of capital expenditures, Vor Biopharma's free cash flow was -$150.7M over the trailing twelve months, down 49.7% year over year.
Where does Vor Biopharma's cash flow data come from?: Every line is extracted from Vor Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.